|
Sep 25
|
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
|
|
Jun 12
|
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
|
|
May 10
|
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
|
|
May 10
|
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
|
|
May 10
|
Q1 2024 Nektar Therapeutics Earnings Call
|
|
May 9
|
Nektar Therapeutics Reports First Quarter 2024 Financial Results
|
|
May 2
|
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
|
|
Apr 3
|
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
|
|
Mar 22
|
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
|
Mar 6
|
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
|
|
Mar 5
|
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
|
|
Mar 5
|
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
|
|
Mar 5
|
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
|
|
Mar 5
|
Q4 2023 Nektar Therapeutics Earnings Call
|
|
Mar 4
|
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 4
|
Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results
|
|
Mar 4
|
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
|
|
Mar 4
|
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
|
|
Jan 9
|
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
|